NAPLES, Fla., Oct. 7, 2021 /PRNewswire/ -- Enveric
Biosciences (NASDAQ: ENVB) ("Enveric" or the
"Company"), a patient-centric biotechnology company developing
next-generation mental health and oncology treatments by leveraging
psychedelic-derived molecules for the mind and synthetic
cannabinoids for the body, today announced that Dr.
Joseph Tucker, Chief Executive
Officer of Enveric Biosciences, will participate in two upcoming
October conferences:
- A.G.P.'s Biotech & Specialty Pharma Conference to be held
virtually on Wednesday, October 13,
2021.
- KCSA Psychedelics Investor Conference to be held virtually at
VirtualInvestorConferences.com from October
13-14, 2021. Dr. Tucker will present live on Wednesday, October 13th at
11:30 a.m. ET. Register to attend
here.
For more information about the conferences, or to schedule a
one-on-one meeting with Enveric's management team, please contact
your representatives directly, or send an email to A.G.P. at
agpevents@allianceg.com or KCSA Strategic Communications at
envericbio@kcsa.com.
About Enveric Biosciences
Enveric
Biosciences (NASDAQ: ENVB) is an innovative biotechnology
company developing a next-generation mental health and oncology
treatment clinical discovery platform, leveraging
psychedelic-derived molecules for the mind and synthetic
cannabinoids for the body. Enveric's robust pipeline supports drug
development from the clinic to commercialization for millions of
patients in need around the world suffering from conditions that
include cancer-related distress, PTSD and more. For more
information, please visit www.enveric.com.
Investor Contacts
Valter
Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com
Media Contacts
Raquel
Cona / Joe McIntyre
KCSA Strategic Communications
212.896.1204 / 856.381.8996
rcona@kcsa.com / jmcintyre@kcsa.com
View original
content:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-october-2021-301394758.html
SOURCE Enveric Biosciences